Therapeutics · AI drug discovery

Junction Bioscience

A one founder startup out of Y Combinator's Winter 2024 batch that says it is building an autonomous AI scientist to formulate drug hypotheses, starting at the intersection of neuroinflammation and immunology. Little about it has been independently verified.

A one line pitch, a lot of unknowns

Junction Bioscience's own description is short and ambitious: an autonomous AI scientist that iterates on laboratory chemistry to find and refine drug hypotheses. The company describes its target zone as the intersection of neuroinflammation and immunology, an area it says holds uncommon molecular insights for best in class therapies.

Beyond that pitch, there is not much to check it against. Junction Bioscience has no listing in the FDA's device or drug databases, no registered clinical trial, no NIH or NSF award under its name, and no paper indexed in the PubMed searches run for this profile. It has also filed no Form D with the SEC, the routine notice most venture backed startups file when they sell equity. For a company two years into its life, that is an unusually quiet public record.

The problem it says it is solving

In its Y Combinator launch post, Junction Bioscience frames the problem as a mismatch between data and judgment. “The global biotechnology industry now faces a human bottleneck where the ability to formulate hypotheses and design rigorous experiments is far outpaced by the deluge of accessible data,” the post reads. The company's argument is that new AI and wet lab tools have made it easier to generate biological data than to ask the right questions about it, and that most of a drug's eventual fate in the clinic is set by choices made years earlier, before there is much chance to backtrack.

Its technical claim centers on measurement. The company says its lab work translates the physical behavior of atoms into what it calls a chemical code, applied to change cellular behavior, and that it has improved the signal to noise ratio for measuring molecular interactions in living cells by a factor of 1000 times. None of that figure has been published or reviewed outside the company's own materials.

The founder

Junction Bioscience lists one active founder, Brian Petkov, as CEO. His company bio describes him as a theoretical physicist and drug hunter with degrees in mathematics and chemistry from Duke University and doctoral training from NYU. The bio says he was previously the first employee and a vice president at a computational drug design startup, where he led machine learning work and grew a 30 person team focused on previously undruggable targets. That prior employer is not named in the materials reviewed for this profile, and no independent account of his tenure there was found. A search for an NYU chemistry thesis defense under his name returned a page that no longer exists.

The company's own account of his decision to start Junction Bioscience is brief: after years in biotechnology, the bio says, he concluded that the major bottlenecks in early drug discovery could be solved by combining AI with wet lab molecular biology techniques that had only recently become available.

What has happened since incorporation

The company's timeline, as it tells it, moves fast. Its Y Combinator launch post says it landed its first six figure partnership within a week of incorporating, and that an early academic case study led to a research collaboration with an unnamed large pharmaceutical company. Neither the partner nor the pharma collaborator has been named in any source found for this profile.

A funding data aggregator, FundedIQ, separately lists one funding round for the company: an undisclosed amount reported as $500,000, dated March 2024, which the tracker places below the median size for biotechnology rounds it tracks. It is not clear from that listing whether it refers to the same six figure deal the company describes as a commercial partnership, to a separate equity raise, or to something else entirely. No SEC Form D corroborates any dollar figure, and no press release announcing a priced round was located.

What is proven, and what is still claimed

Read plainly, almost everything specific about Junction Bioscience, its named partnerships, its dollar amounts, its founder's prior employer, its 1000x measurement claim, comes from the company itself or from commercial data trackers that do not show their underlying source. The only fixed points outside that are its listing in the Y Combinator Winter 2024 batch and the absence of any SEC, FDA, NIH, NSF or clinical trial record under its name.

What to watch

• Whether a Form D or a named, priced round ever appears on SEC EDGAR, which would settle the funding question one way or another.
• Whether the company names its first pharma collaborator or its first six figure partner.
• Whether Brian Petkov's prior employer, described only as a computational drug design startup, is ever named in an independent source.
• Whether the company's stated headquarters, New York City, is confirmed or corrected against the San Francisco listings carried by commercial trackers.
• Whether any of the company's technical claims, including the 1000x signal to noise figure, appear in a peer reviewed paper or preprint.

In their words

Related companies

• 1910 Genetics: Also in Therapeutics. A Boston biotech that runs small and large molecule drug discovery through one AI platform, backed by a five-year commercial partnership with Microsoft
• PipeBio: Also in Therapeutics. A five person Danish company that built cloud bioinformatics for antibody discovery, got its name into the methods sections of twenty published papers, and was bought by
• FinalDose: Also in Therapeutics. A one month old London biotech says it has built a single drug molecule that can be reprogrammed to find and kill any cell carrying a chosen DNA sequence, starting with
• Tradewind BioScience: Also in Therapeutics. A two person antibody company built around EGFL6, a secreted protein that ovarian tumors make and healthy adult tissue mostly does not

Sources

1. Public recordJunction Bioscience company profile and Launch YC post, Winter 2024 batchY Combinator · accessed Sep 25, 2026
2. IndependentJunction Bioscience: Illuminating the Pathways to Medical InnovationHiretop, Daryna Falko · May 2, 2024
3. IndependentJunction Bioscience funding profileFundedIQ · accessed Sep 25, 2026, funding dated Mar 2024
4. IndependentJunction Bioscience company profileCyberLeads · accessed Sep 25, 2026
5. Not foundJunction Bioscience organization page, no financial or deal data on recordSynapse by Patsnap · accessed Sep 25, 2026
6. Public recordSEC EDGAR full text search for “Junction Bioscience,” unfiltered and filtered to Form D, zero resultsSEC EDGAR · Sep 25, 2026
7. Not foundNSF, NIH, FDA, ClinicalTrials.gov and PubMed searches for Junction Bioscience, no matching recordCompiled Sep 25, 2026
8. CompanyJunction Bioscience website homepageInternet Archive Wayback Machine snapshot · Dec 6, 2025